Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Massive Reallocation of UK Rapporteurships Likely As EMA Plans For Future; UK’s Interim Role Uncertain

Executive Summary

If Brexit means the UK no longer plays a part in the EU drug regulatory system, responsibility for the ongoing oversight of almost one in four of all the human medicines that have ever been approved under the centralized procedure will have to be reassigned from the UK to other member states. What Brexit means for the UK’s role as a key player in the regulatory system in the meantime is the subject of speculation.

You may also be interested in...

UK MHRA ‘Pushback’ Against Efforts To Sideline It From EU Processes

The EMA says the UK is continuing to bid for EU regulatory work as the Brexit date of March 29, 2019 draws nearer. The head of the BioIndustry Association says this is something of a “pushback” against efforts to squeeze the UK out of its EU regulatory role in preparation for Brexit.

‘We’re Still In The EU!’ UK MHRA Insists As Brexit Talks Move Into Phase 2

The UK MHRA says it plans to continue playing a full part in the EU regulatory network as Brexit negotiations continue, while a task force at the EU industry body EFPIA has discussed contingency planning and other issues.

‘Not Enough Time’ To Transfer All Marketing Authorizations In Case Of ‘No-Deal’ Brexit, says EFPIA

A survey of EFPIA member companies has revealed some alarming statistics on the effects that a “no-deal” Brexit would have on trade, marketing authorizations, batch release and clinical trials.

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts